Provided by Tiger Trade Technology Pte. Ltd.

Repligen

170.02
-10.9600-6.06%
Post-market: 170.020.00000.00%17:24 EDT
Volume:1.41M
Turnover:239.87M
Market Cap:9.57B
PE:232.90
High:182.57
Open:180.70
Low:167.42
Close:180.98
52wk High:188.73
52wk Low:100.99
Shares:56.29M
Float Shares:53.32M
Volume Ratio:1.80
T/O Rate:2.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.7300
EPS(LYR):0.8600
ROE:1.99%
ROA:1.40%
PB:4.53
PE(LYR):197.70

Loading ...

U.S. Research Roundup-Autodesk, Hubspot, Oracle

Reuters
·
Yesterday

Repligen (RGEN) Dropped, So What Is Behind The Latest Attention?

Simply Wall St.
·
Aug 29

Will Stronger 2026 Guidance and Broad-Based Growth Change Repligen's (RGEN) Narrative

Simply Wall St.
·
Aug 28

Repligen CEO, CFO to Join Wells Fargo Healthcare Conference Analyst Discussion

Reuters
·
Aug 26

Repligen CEO Olivier Loeillot Disposes of 5,426 Common Shares Worth $976,680

Reuters
·
Aug 22

Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF) and Repligen (RGEN)

TIPRANKS
·
Aug 21

Q/C Technologies CFO Todd Fagan Files Initial Beneficial Ownership Statement

Reuters
·
Aug 18

Q/C Technologies Q2 Net Loss Widens to $6.62 Million; Operating Loss Widens to $6.79 Million

Reuters
·
Aug 13

BioLife Solutions Swings to Q2 FY26 GAAP Net Income of $45.1 Million; Revenue Rises 21% to $28.5 Million vs Q2 FY25

Reuters
·
Aug 07

Q/C Technologies Names Yossef Ehrlichman Founding Manager of Photonic Integrated Circuit Development

Reuters
·
Aug 04

BioLife Details Strategic Repligen Merger Communication to Staff

TIPRANKS
·
Aug 04

Repligen Says BioLife Deal Targets Q4 Close Pending Regulatory, Shareholder Approvals

Reuters
·
Aug 04

Repligen is Maintained at Overweight by Wells Fargo

Dow Jones
·
Jul 30

Switzerland's Bachem H1 Sales Rise 4.3% on Growth in Clinical Drug Development

Reuters
·
Jul 30

Beta Bionics Q2 Sales Beat Estimates on Pharmacy Channel Growth

Reuters
·
Jul 30

Analysts’ Top Healthcare Picks: Repligen (RGEN), Allogene Therapeutics (ALLO)

TIPRANKS
·
Jul 30

Repligen's Diversity of Growth Drivers Support Return to Mid-Teens Organic Sales Growth, RBC Says

MT Newswires Live
·
Jul 30

Repligen’s Operational Momentum Offset by Full Valuation; Kyle Mikson CFA Reiterates Hold with Unchanged $145 Price Target

TIPRANKS
·
Jul 29

Repligen Stock (RGEN) Rises After Investors Wowed By ‘Market Leading’ Q2 Figures

TIPRANKS
·
Jul 29

RBC Raises Price Target on Repligen to $185 From $160, Keeps Outperform Rating

MT Newswires Live
·
Jul 29